Home > Insider Trading > Filing (0001562180-25-000917)

Filing Details

Accession Number:: 0001562180-25-000917
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2025-02-04 17:54:18
Reporting Period:: 2025-01-31

Filing Date:: 2025-02-04
Accepted Time:: 2025-02-04 17:54:18
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1517022	Akebia Therapeutics Inc.	AKBA	Pharmaceutical Preparations (2834)	208756903

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1591467	P. John Butler	C/O Akebia Therapeutics, Inc. 245 First Street Cambridge MA 02142	Ceo And President	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2025-01-31	701,000	$0.00	2,748,580	No	4	A	Direct
Common Stock	Disposition	2025-02-03	46,268	$2.10	2,702,312	No	4	S	Direct
Common Stock	Disposition	2025-02-03	97,982	$2.10	2,604,330	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Performance Stock Units	Acquisiton	2025-01-31	350,500	$0.00	350,500	$0.00
Common Stock	Stock Option (Right to buy)	Acquisiton	2025-01-31	1,051,400	$0.00	1,051,400	$2.24

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
350,500		2027-01-31	No	4	A	Direct
1,051,400		2035-01-31	No	4	A	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	100,000	Indirect	Held By John Butler GRAT November 2019
Common Stock	59,928	Indirect	Held by John Butler 2019 GRAT
Common Stock	100,000	Indirect	Held By Dorothy Butler GRAT November 2019
Common Stock	59,928	Indirect	Held by Dorothy Butler 2019 GRAT

Footnotes

The restricted stock units were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date.
Includes 1,500 shares of the Issuer's common stock purchased on June 28, 2024 and 1,500 shares of the Issuer's common stock purchased on December 31, 2024, each under the Issuer's Amended and Restated 2014 Employee Stock Purchase Plan.
This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2023.
This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2023.
This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2024.
Each Performance Stock Unit ("PSU") right represents a contingent right to receive one share of the Issuer's common stock. One-half of the total number of shares of common stock underlying the PSUs shall vest on each of (a) the later of (i) the first anniversary of the grant date and (ii) the date that the Compensation Committee certifies that the average closing price of the Issuer's common stock equals or exceeds $3.50 over a 30-day trading period, and (b) the later of (i) the first anniversary of the grant date and (ii) the date that the Compensation Committee certifies that the average closing price of the Issuer's common stock equals or exceeds $5.00 for over a 30-day trading period, subject to the reporting person's continued service with the Issuer through the applicable vesting date.
The options were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.